Last reviewed · How we verify

Recombinant fimbrial adhesin dscCfaE

U.S. Army Medical Research and Development Command · Phase 1 active Biologic

Recombinant fimbrial adhesin dscCfaE is a Biologic drug developed by U.S. Army Medical Research and Development Command. It is currently in Phase 1 development. Also known as: dscCfaE.

At a glance

Generic nameRecombinant fimbrial adhesin dscCfaE
Also known asdscCfaE
SponsorU.S. Army Medical Research and Development Command
ModalityBiologic
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Recombinant fimbrial adhesin dscCfaE

What is Recombinant fimbrial adhesin dscCfaE?

Recombinant fimbrial adhesin dscCfaE is a Biologic drug developed by U.S. Army Medical Research and Development Command.

Who makes Recombinant fimbrial adhesin dscCfaE?

Recombinant fimbrial adhesin dscCfaE is developed by U.S. Army Medical Research and Development Command (see full U.S. Army Medical Research and Development Command pipeline at /company/u-s-army-medical-research-and-development-command).

Is Recombinant fimbrial adhesin dscCfaE also known as anything else?

Recombinant fimbrial adhesin dscCfaE is also known as dscCfaE.

What development phase is Recombinant fimbrial adhesin dscCfaE in?

Recombinant fimbrial adhesin dscCfaE is in Phase 1.

Related